American Cyanamid Company

Schering Corporation

Michael J Ryan

Jason Arnold Lotvin

Paul J Leibowitz

Elizabeth B Smith

Susan E Fantini

Nancy Strathy

Satwant K Narula

George H Miller

Richard L Reim

Karen J Shaw

Hanan K Munayyer

Recombinant S. aureofaciens cells are provided. These cells comprise:

Strain for the production of 6-dimethyltetracycline, method for

Recombinant S. aureofaciens cells are provided. These cells comprise: (a) at least one CTC 11 gene; and (b) optionally

Strain for the production of 6-demethyltetracycline, method for

The present invention describes a purified and isolated nucleic acid molecule which encodes for the biosynthetic pathway of tetracycline, chlortetracycline or an analogue thereof. The invention relates to the isolation and cloning of the nucleic acid molecule in an isolated fragment from Streptomyces aureofaciens and the expression of the biosynthetic gene in a heterologous host such as Streptomyces lividans.

Cloning of the biosynthetic pathway for chlortetracycline and

7-Chloro-8-methoxytetracycline isolated from antibiotic ES-119 and antibiotic Tet. 7 which are produced by fermentation of mutants of Actinomadura brunnea, namely Actinomadura brunnea var. antibiotica, ATCC 53108 and Actinomadura brunnea var antibiotica ATCC 53180 and its use as an antibiotic against gram-positive and gram-negative organisms are disclosed.

Actinomadura brunnea var. antibiotica strains

Methods of constructing and using gene expression systems to indicate the pertubation of fungal cell envelopes are provided. The recombinant genes produce indicator cleavage enzymes such as .beta.-galactosidase when galactose is able to enter the cell, despite the presence of glucose, through discontinuous cell envelopes. The indicator cleavage enzymes such as .beta.-galactosidase cleaves a colorimetric indicator placed in the media to produce an easily detected measurement of altered cell envelope permeability.

Colorimetric assay for detecting fungal cell envelope perturbations

Expression systems which utilize bacteriophage T7 RNA mutant polymerases and promoter regions are provided by this invention. These systems are utilized to produce large quantities of useful polypeptides and proteins.

Expression systems utilizing bacteriophage T7 promoters, gene sequences,

The invention features a novel hybrid interferon species that comprises a chain of 161 and/or 162 amino acids. The hybrid is novel not only for its new structure, but also because the hybrid comprises a shortened or truncated segment of alpha interferon, and hence, an entirely new interferon species which is not occurring in nature.

Growing community of inventors

West Milford, NJ, United States of America

Michael J Ryan